Can I Take 5-HTP with Crestor (Rosuvastatin)?

What Is 5-HTP and Why Do People Take It?

5-Hydroxytryptophan (5-HTP) is a naturally occurring amino acid and the direct biochemical precursor to serotonin (5-hydroxytryptamine, 5-HT). The body synthesizes it from dietary tryptophan via the enzyme tryptophan hydroxylase. Sold over the counter in doses typically ranging from 50 mg to 400 mg per capsule, 5-HTP is marketed for mood support, appetite control, sleep quality, and anxiety relief.

The Serotonin Pathway

After oral ingestion, 5-HTP crosses the blood-brain barrier and is decarboxylated to serotonin by aromatic L-amino acid decarboxylase (AADC). Because this conversion happens both peripherally (gut, liver, platelets) and centrally (raphe nuclei), a single 100 mg dose can raise plasma serotonin measurably within 90 minutes. A small double-blind crossover study (N=15) published in Neuropsychopharmacology confirmed significant elevations in urinary 5-hydroxyindoleacetic acid, the primary serotonin metabolite, after a single 100 mg dose.

Why the Precursor Route Matters Clinically

Unlike tryptophan, 5-HTP bypasses the rate-limiting tryptophan hydroxylase step entirely. That means even modest supplement doses push serotonin synthesis faster than tryptophan-rich foods could. Peripherally, excess serotonin acts on 5-HT2B receptors in skeletal muscle, where it modulates mitochondrial biogenesis and calcium handling. This receptor expression in muscle tissue is the biological basis for the indirect concern with statins.

How Rosuvastatin (Crestor) Works and Its Known Side Effect Profile

Rosuvastatin is an HMG-CoA reductase inhibitor approved by the FDA in 2003 for hyperlipidemia, mixed dyslipidemia, and primary prevention of cardiovascular events in high-risk patients. FDA prescribing information for rosuvastatin (NDA 021366) lists myopathy, rhabdomyolysis, and hepatic enzyme elevations as the principal serious adverse effects.

Pharmacokinetics: The CYP Profile That Matters

Rosuvastatin is metabolized primarily by CYP2C9 (minor) and is largely excreted unchanged. It is not a meaningful CYP3A4 substrate, which is an important distinction from atorvastatin and simvastatin. A 2004 pharmacokinetic review in Clinical Pharmacokinetics confirmed that rosuvastatin has low hepatic extraction and minimal CYP3A4 involvement, reducing its susceptibility to many drug-supplement CYP interactions.

5-HTP metabolism runs through AADC and monoamine oxidase (MAO), not through CYP enzymes. This means the two compounds do not compete for the same metabolic enzymes at standard doses. A pharmacokinetic interaction (one altering the plasma concentration of the other) is not expected and has not been reported in the literature.

Statin-Associated Muscle Symptoms (SAMS)

Statin-associated muscle symptoms affect approximately 7 to 29 percent of statin users in observational studies, though randomized controlled trials using objective CK thresholds report lower rates. The SAMSON trial (N=60, crossover design) published in JACC in 2020 found that 90% of statin muscle symptoms were attributable to nocebo effect, with only a 9% absolute difference in symptom scores between rosuvastatin 20 mg and placebo. Still, true myopathy occurs, and its mechanism involves mitochondrial dysfunction, coenzyme Q10 depletion, and impaired calcium homeostasis in the sarcolemma.

The Actual Interaction Between 5-HTP and Rosuvastatin

No published case report, randomized trial, or pharmacovigilance signal in the FDA Adverse Event Reporting System (FAERS) documents a direct, clinically harmful interaction between 5-HTP and rosuvastatin specifically. That absence of evidence is meaningful, though not a final guarantee of safety.

Pharmacodynamic Overlap: Muscle Risk

The indirect concern is pharmacodynamic. Serotonin receptors, particularly 5-HT2A and 5-HT2B, are expressed in skeletal muscle. A 2013 paper in PLOS ONE demonstrated that 5-HT2B receptor signaling in cardiac and skeletal myocytes regulates sarcomere organization and mitochondrial function. Statins independently impair mitochondrial respiratory chain complexes I and III. Theoretically, raising serotonergic tone while mitochondria are already under statin-mediated stress could compound muscle cell vulnerability.

This theoretical additive myotoxicity has not been quantified in a clinical trial. The signal is mechanistically plausible, not proven. Patients who already experience mild muscle aching on rosuvastatin should interpret this as a reason for closer monitoring, not automatic contraindication.

The Serotonin Syndrome Question

Serotonin syndrome is a triad of neuromuscular abnormalities (clonus, hyperreflexia, tremor), autonomic instability (hyperthermia, tachycardia, diaphoresis), and altered mental status. The Hunter Serotonin Toxicity Criteria, validated in a prospective cohort and published in QJM in 2003, define the diagnostic standard and require at least one specific neuromuscular finding in the setting of a serotonergic agent.

Rosuvastatin is not a serotonergic agent. It does not inhibit serotonin reuptake, stimulate serotonin receptors, or impair serotonin metabolism. On its own, rosuvastatin adds zero serotonergic load. The serotonin syndrome risk becomes relevant only when 5-HTP is combined with a separate serotonergic drug that the patient also happens to take alongside their statin. Common examples include:

• Selective serotonin reuptake inhibitors (SSRIs): sertraline, escitalopram, fluoxetine
• Serotonin-norepinephrine reuptake inhibitors (SNRIs): venlafaxine, duloxetine
• Tramadol or meperidine (opioids with serotonin reuptake inhibition)
• Monoamine oxidase inhibitors (MAOIs): phenelzine, selegiline
• Triptans: sumatriptan, rizatriptan

If a patient takes rosuvastatin AND an SSRI AND then adds 5-HTP, the rosuvastatin is a bystander, but the SSRI-plus-5-HTP combination carries real serotonin syndrome risk. A 2016 case series in Drug Safety catalogued 14 cases of serotonin syndrome involving 5-HTP combined with standard serotonergic medications, with symptom onset within 6 hours of combined ingestion in 11 of 14 cases.

A Decision Framework: How to Assess Your Specific Risk

Before taking 5-HTP alongside rosuvastatin, work through these four questions with your prescriber:

1. Are you on any serotonergic drug? If yes, 5-HTP carries meaningful serotonin syndrome risk regardless of the statin.
2. Do you have current muscle symptoms on rosuvastatin? If yes, adding a supplement that may compound myotoxicity is lower priority than first optimizing the statin dose or switching to an alternative.
3. What dose of 5-HTP are you considering? Doses at or below 100 mg/day carry lower serotonergic burden than the 300 to 400 mg doses used in some sleep trials.
4. Do you have CK levels on file? A baseline CK measurement before adding any new supplement to a statin regimen creates a reference point for monitoring.

Pharmacokinetic Detail: Why CYP Enzymes Are Not the Issue Here

Pharmacokinetic interactions occur when one substance changes the absorption, distribution, metabolism, or excretion of another. For statin interactions, CYP3A4 inhibition is the most common culprit. Gemfibrozil, for example, inhibits the OATP1B1 transporter and can raise rosuvastatin area under the curve (AUC) by up to 2-fold, increasing myopathy risk. The 2022 ACC Expert Consensus Decision Pathway on Statin Safety explicitly lists OATP1B1 inhibitors and CYP3A4 inhibitors as clinically relevant for statin interactions.

5-HTP does not inhibit OATP1B1 at physiological doses. It does not meaningfully inhibit CYP2C9 either. No pharmacokinetic interaction study has found that 5-HTP alters rosuvastatin plasma concentrations. The available evidence, while limited by the absence of a dedicated clinical trial, points consistently away from a pharmacokinetic concern.

What the Guidelines Say About Statin-Supplement Interactions Generally

Neither the 2018 AHA/ACC Cholesterol Guideline nor the 2022 ACC Expert Consensus Decision Pathway on Statin Safety mentions 5-HTP specifically. This gap reflects how rarely dietary supplements are formally evaluated against individual statins in large trials.

The 2018 guideline does state, in the section on lifestyle modification and drug interactions: "Clinicians should ask patients about all supplements and herbal products at each visit, as these may alter statin metabolism or contribute to adverse effects." The full 2018 AHA/ACC Cholesterol Guideline is available via the AHA Journals.

The Natural Medicines database (formerly Natural Standard), widely used by pharmacists, rates the rosuvastatin-5-HTP combination as having insufficient evidence to assign a formal interaction severity grade, which differs from a "no interaction" rating.

Coenzyme Q10 and the Statin Context

Many patients taking statins also supplement with coenzyme Q10 (CoQ10), a biologically reasonable choice given that statins reduce endogenous CoQ10 synthesis via the same mevalonate pathway. Some patients take CoQ10, 5-HTP, and a statin simultaneously. No interaction has been identified between CoQ10 and 5-HTP, and CoQ10 is generally considered low-risk with statins, though evidence of clinical benefit on SAMS remains mixed. A 2018 Cochrane-adjacent meta-analysis in Medicine (N=12 trials, 1,776 participants) found that CoQ10 supplementation did not significantly reduce statin-related muscle pain scores versus placebo (SMD -0.37, 95% CI: -0.85 to 0.10, P = 0.13).

Monitoring Recommendations If You Choose to Take Both

If, after discussion with your prescriber, you proceed with 5-HTP while taking rosuvastatin, a structured monitoring approach reduces risk.

Baseline Labs Before Starting 5-HTP

• Creatine kinase (CK): establishes a pre-supplement reference
• Comprehensive metabolic panel (CMP): includes liver function tests (AST, ALT), which rosuvastatin can raise at higher doses
• Thyroid-stimulating hormone (TSH): hypothyroidism is an independent risk factor for both statin-related myopathy and low mood, the very condition 5-HTP is often taken for

Symptom-Based Monitoring

Report to your provider immediately if you notice:

• New or worsening muscle pain, weakness, or tenderness within 4 to 8 weeks of starting 5-HTP
• Dark or cola-colored urine (a rhabdomyolysis warning sign)
• Agitation, rapid heart rate, sweating, or muscle twitching (early serotonin toxicity signs, especially if you are also on a serotonergic drug)

Dose Considerations

Starting 5-HTP at the lowest effective dose (50 mg at bedtime, a common starting point for sleep support) and titrating slowly gives the body time to adjust and makes any new symptom easier to attribute. Doses above 200 mg/day without clinical supervision are generally not recommended alongside any medication that affects serotonin, and some evidence suggests peripheral serotonin excess at very high doses can cause nausea and GI motility changes that mimic other side effects. A controlled dose-escalation trial published in Alternative Therapies in Health and Medicine found that 5-HTP doses of 150 to 300 mg/day produced significant GI adverse effects in 26% of participants at the 300 mg level.

Special Populations: Who Needs Extra Caution

Patients on Multiple Serotonergic Medications

As discussed above, the serotonin syndrome risk is not about rosuvastatin. It is about any co-administered serotonergic drug. Patients on two serotonergic agents (say, an SSRI plus buspirone) who then add 5-HTP enter genuinely high-risk territory. The statin is irrelevant to that calculus.

Older Adults

Adults over 65 carry higher baseline risk for both statin myopathy and serotonin sensitivity. The 2018 AHA/ACC guideline recommends starting statins at lower doses in older adults due to altered pharmacokinetics and polypharmacy. Adding 5-HTP to a multi-drug regimen in this group warrants explicit pharmacist review, not just a patient's independent judgment.

Patients with Chronic Kidney Disease (CKD)

Rosuvastatin dose should not exceed 10 mg/day in patients with severe CKD (eGFR <30 mL/min/1.73m²) per FDA labeling. CKD also reduces renal clearance of serotonin metabolites. The combination may raise systemic serotonin metabolite exposure more than expected in this population.

Patients with Hepatic Impairment

Both rosuvastatin and 5-HTP are hepatically processed. Active liver disease is a contraindication to rosuvastatin per prescribing information. 5-HTP undergoes hepatic decarboxylation, and significant liver impairment could alter its conversion kinetics.

What to Tell Your Doctor

Bring a clear, specific list when you see your prescriber. Tell them:

1. The exact brand, dose, and frequency of 5-HTP you intend to use.
2. Every other supplement in your current stack.
3. Any current muscle symptoms, even mild.
4. Whether you are on any serotonergic medication.

A prescriber cannot assess risk from vague descriptions. Specifics allow a targeted CK check, a medication reconciliation review, and, if needed, a dose adjustment to rosuvastatin before you begin.

The Bottom Line on Safety Evidence

The interaction between 5-HTP and rosuvastatin is not well-studied in dedicated clinical trials, and no formal interaction has been reported in pharmacovigilance databases. The absence of direct interaction evidence should not be read as a blanket safety assurance. The theoretical pharmacodynamic concern centers on additive muscle mitochondrial stress, not on serotonin syndrome (which requires a co-administered serotonergic drug). For most patients taking rosuvastatin at standard doses (10 to 20 mg/day) with no current muscle symptoms and no serotonergic comedications, adding 5-HTP at 50 to 100 mg/day may be low risk but should be done under medical supervision with a baseline CK measurement obtained first.